Pharmaceutical and Medicine Manufacturing (United States) — NAICS 32541

NAICS 2022 industry code 32541. NAICS = North American Industry Classification System, the U.S. government's standard scheme for grouping businesses. This is a five-digit "industry" that sits one level above its four component industries and one level below the broader chemical-manufacturing subsector.

---

1. Overview

This is the whole of U.S. medicine-making, gathered under one code: the businesses that make the active ingredients, the finished pills and shots, the vaccines and blood-and-cell therapies, and the diagnostic reagents that the health-care system runs on. If it is manufactured, taken by (or tested on) a patient, and regulated by the Food and Drug Administration (FDA) as a drug, biologic, or diagnostic, its factory is somewhere inside NAICS 32541.

Why an investor should care: this is one of the largest, most defensive, highest-margin, and most heavily regulated manufacturing industries in the economy. Underlying demand — an aging, chronically ill population that keeps taking medicine in booms and recessions alike — is durable and largely non-cyclical. A 2025 CDC study found that 76% of U.S. adults reported at least one chronic condition and 51% reported two or more [1]. But the industry is not one business; it is four very different businesses with genuinely opposite economics stapled together by a shared regulator. One runs on patent monopolies, one on commodity chemistry, one on a razor-and-blade annuity, and one on biological exclusivity. The distinctive value of looking at the whole industry is seeing how those four compare — which is large, which is growing, who owns each, and how a public-market or private investor actually reaches it.

The single most important fact about the group: one child, Pharmaceutical Preparation Manufacturing (finished pills and shots), is roughly two-thirds of it by revenue. The other three — biologics, diagnostic reagents, and bulk active ingredients — split the rest and behave nothing alike. Sections 2–3 make that contrast concrete; Sections 4–10 cover the industry as a whole.

---

2. What's inside — the four child industries, and how they differ

NAICS 32541 splits into four industries. They are not four slices of the same pie; they are four different foods.

• 325411 — Medicinal and Botanical Manufacturing. The active pharmaceutical ingredient (API) — the actual chemical that treats disease — plus bulk medicinal chemicals and plant-derived (botanical) actives. The raw drug substance, before it becomes a pill.
• 325412 — Pharmaceutical Preparation Manufacturing. The "formulate and fill" step: turning ingredients into finished dose forms — tablets, capsules, injectables, ointments, solutions. The core manufacturing arm of the branded- and generic-drug industries.
• 325413 — In-Vitro Diagnostic Substance Manufacturing. The reagents, test kits, calibrators, and controls used to run diagnostic tests on samples taken outside the body (blood, urine, swabs) — the consumables an analyzer burns, not the analyzer itself.
• 325414 — Biological Product (except Diagnostic) Manufacturing. Biologics — medicines grown from living cells rather than mixed from chemicals: vaccines, plasma-derived therapies, monoclonal antibodies (lab-grown antibodies against cancer and autoimmune disease), and gene and cell therapies.

The contrast table

(Receipts shares are computed from the federal ground-truth figures in Section 3; they are shares of U.S. domestic factory output, not of company revenue or of what Americans consume.)

The one-line reading. 325412 is the giant that most people picture when they hear "the pharma industry." 325414 (biologics) is the smaller but faster-growing future of medicine — as of March 2026, FDA noted that biologics account for only 5% of U.S. prescriptions but 51% of drug spending [2]. 325413 (diagnostics) is a high-quality, sticky annuity. 325411 (APIs) is a small, strategically contested, mostly-imported upstream link that policy is now trying to rebuild. Four industries, four investment cases.

Note on the boundaries. These codes predate the biologics boom and the real world blurs them: an integrated company that synthesizes an API and formulates the pill at one site is usually filed under 325412, so much API-making is invisible to 325411; a Roche or an Abbott spans 325412, 325413, and 325414 at once. That straddling is visible even in the counts — the four children list 2,292 firms between them, but the industry as a whole counts only 2,222 firms [3], because a company operating in more than one child is counted once here.

---

3. How big it is (federal ground truth)

Our ingested federal statistics for NAICS 32541 as a whole:

How the four children add up. The level figures are the sum of the parts, which lets us show where the weight sits:

Three things stand out. First, the size skew: finished-drug manufacturing (325412) is nearly two-thirds of revenue and over half the jobs; bulk-API making (325411) is under 6% of revenue despite having a quarter of all the plants — because API work is capital- and chemistry-intensive, spread across many small, low-wage sites (~$77k average pay, far below the group's ~$114k). Second, the wage gradient tracks the science: biologics (~$125k) and diagnostics (~$115k) are scientist- and engineer-heavy; commodity chemistry pays least. Third, medicine manufacturing pays well: the group average of ~$114,000 sits well above the manufacturing norm, reflecting regulated, skilled work throughout.

The undercount caveat (large, and it runs in two directions). The $234.2 billion is U.S. domestic factory-gate output — the value of what plants on U.S. soil ship. It is neither what Americans spend on medicine nor the global revenue of the companies involved, and it understates the true footprint for several reasons:

1. Factory gate, not pharmacy counter. Receipts are valued before wholesale, pharmacy, and middleman markups. U.S. prescription-drug spending alone reached about $805.9 billion in 2024, up 10.2% year over year [5] — more than three times this industry's entire domestic output, and that figure is only the finished-drug slice.
2. Much of what we consume is imported. The U.S. imports most of its bulk APIs and a large share of finished and biologic product. FDA reports that approximately 53% of branded finished drugs and 69% of generic finished drugs distributed in the United States were manufactured abroad, and only 11% of API manufacturers were U.S.-based [6]. Private estimates put the U.S. API market near $87 billion [7], the U.S. in-vitro-diagnostics market around $35 billion [8], and the U.S. biologics market well north of $200 billion [9] — all consumption measures far larger than the corresponding domestic-output codes.
3. Only manufacturing plants are counted. A drug company's scientists (a research code), headquarters, and sales force sit in other NAICS codes. The 321,068 factory workers here understate a biopharmaceutical industry that directly employs over 1 million Americans [10].
4. A dispersed small-owner tail is easily misclassified, concentrated in the API/botanical child (325411): small herbal, cannabinoid/hemp, vitamin, and supplement-ingredient operators — many privately held — are often filed into food, chemical, or supplement codes instead. Where small and individual ownership dominates, the federal count is a floor, not a ceiling.

Read the $234 billion as an accurate read on the domestic manufacturing footprint — real and useful — sitting inside a much larger consumption-and-services economy that is served heavily from abroad.

---

4. The investable universe — where value concentrates across the children

The four children are not equally reachable, and that is the first thing an allocator should internalize.

• 325412 (finished drugs) holds nearly all the public liquidity. This is where the household names trade, directly or as American Depositary Receipts (ADRs — U.S.-traded certificates representing foreign shares): Johnson & Johnson (JNJ, $60.4 billion drug segment in 2025), Eli Lilly (LLY, $65.2 billion, +45%), Merck (MRK, $65.0 billion), Pfizer (PFE, $62.6 billion), AbbVie (ABBV, $61.2 billion), Bristol Myers Squibb (BMY, $48.2 billion), Amgen (AMGN, $36.8 billion), Gilead (GILD, $29.4 billion), plus foreign majors AstraZeneca (AZN, $58.7 billion), Novartis (NVS, $54.5 billion), and Novo Nordisk (NVO). Generics and contract makers — Teva (TEVA), Viatris (VTRS) — sit below them. If you own "pharma," you almost certainly own this child. [11]
• 325414 (biologics) is owned in focused pieces. Near pure-plays exist — immune-globulin specialist ADMA Biologics (ADMA, $510 million revenue, 57% gross margin in 2025), vaccine developers Moderna (MRNA) and Novavax (NVAX), biodefense supplier Emergent (EBS, $743 million revenue, 45% gross margin) — alongside plasma majors reached mostly through foreign listings or ADRs (CSL at ~$15.6 billion, Grifols/GRFS at ~€7.2 billion, Takeda/TAK), and the biologic franchises buried inside diversified pharma (Merck's Keytruda, a monoclonal antibody, is a ~$32 billion product on its own [12]).
• 325413 (diagnostics) has no pure-play reagent stock at all. It is owned as one segment inside diversified leaders — Abbott (ABT, $8.9 billion diagnostics), Danaher (DHR, $9.9 billion), Thermo Fisher (TMO), Roche (RHHBY, ~$16 billion diagnostics division), Siemens Healthineers (SHL, €4.4 billion) — with harder-tilted mid-caps such as QuidelOrtho (QDEL, $2.7 billion), Hologic (HOLX, $1.8 billion diagnostics), Bio-Rad (BIO, $1.6 billion clinical diagnostics), and Qiagen (QGEN, ~$2.0 billion). [13]
• 325411 (bulk APIs) has no U.S. pure-play whatsoever. Exposure comes from foreign-listed API/contract specialists (Lonza at CHF 6.5 billion 2025 sales with 31.6% EBITDA margin, Divi's Laboratories at ~$22 billion market cap, Dr. Reddy's/RDY, Siegfried at 23.5% EBITDA margin), U.S. diversified names with API lines (Thermo Fisher, Mallinckrodt/MNK, Amphastar/AMPH), ingredient/nutrition firms for the vitamin-and-botanical slice (DSM-Firmenich, Balchem/BCPC, IFF), and — most purely — private owners. [14][15]

The private layer is large and cuts across children. The purest assets are frequently private: the emblem is Catalent, a leading contract developer/manufacturer spanning API, fill-finish, and biologics work, taken private by Novo Holdings for about $16.5 billion in December 2024 [16]. Private equity owns API specialists (Cambrex under Permira) and reagent platforms (Ortho Clinical Diagnostics was Carlyle-owned before its 2022 merger), and privately held plasma fractionators (Octapharma, Kedrion) and the botanical/vitamin tier round out a deep non-listed universe. For every child, private equity, venture capital, and — for biologics/biodefense — the U.S. government are meaningful owners.

(Tickers here are orientation, not recommendations. Every listed name carries large businesses outside this industry, and shares, dividends, and valuations change constantly.)

---

5. How the money works

The unifying theme is that all four children enjoy defensive demand, high fixed costs, and a regulatory moat — but the source of the moat, and therefore the economics, is different in each.

• 325412, the patent model. A branded drugmaker spends years and well over a billion dollars to discover, prove, and win approval for a drug; most candidates fail (the industry spent roughly $96 billion on R&D in 2023 [10]). The payoff is a patent-protected monopoly with gross margins commonly 70–90% — Eli Lilly reported a consolidated gross margin of roughly 83% in 2025 [17]. Revenue is extremely concentrated in a handful of blockbusters (drugs earning over $1 billion a year), and the whole model turns on the calendar — loss of exclusivity (LOE), when patents lapse and copies enter, can collapse a drug's revenue 80–90% within a year. Generic makers are the mirror image: no monopoly, thin margins (Teva ran ~49.5%, Viatris ~35%), competition on price and scale. [18][19]
• 325414, the exclusivity-plus-capacity model. A biologic gets 12 years of data exclusivity before a "biosimilar" copy can be approved [20], and its plants are hugely expensive ($1–2 billion, years to build), so profit turns on keeping bioreactors and fill-finish lines full and on yield. Plasma is its own animal — a vertically integrated supply chain that pays human donors, then fractionates each liter into immune globulin, albumin, and clotting factors; the U.S. supplies roughly 70% of the world's source plasma, and blood products are around 1.8% of total U.S. goods exports (~$37 billion) [21]. Some demand (biodefense, stockpiles) is lumpy government procurement.
• 325413, the razor-and-blade annuity. A maker places an analyzer in a lab — often cheaply — then sells the proprietary reagents it consumes for years. The operating metric is the installed base × reagent pull-through (revenue per instrument per year), lab contracts run 5–7 years, switching is slow and validated, and mature franchises carry very high recurring revenue (Danaher reported 89% recurring products in its Diagnostics segment in 2025 [22]). It behaves more like a consumables subscription than episodic equipment sales.
• 325411, the specialty-chemistry model. These are process manufacturers whose economics look like fine chemicals: plant utilization is the biggest profit lever, input costs (solvents, catalysts, imported key starting materials) are the main variable cost, and the money is in complex, niche, high-potency, or controlled products rather than commodity generics that chronically deflate. The moat is regulatory stickiness — once a specific ingredient source is written into an approved drug application (via a confidential Drug Master File (DMF)), switching suppliers requires new filings, so qualified supply contracts are long-lived. Independent makers run this as a contract (CDMO) business: win the molecule early, keep the volume for its commercial life.

How owners get paid also differs: mature branded, generic, diagnostics, and plasma firms return cash through dividends and buybacks; clinical-stage biotech pays nothing and burns cash funded by equity; royalty investors buy a slice of a drug's future sales for cash today. Several genuinely different investments live under one industry label.

---

6. What drives demand

Most demand drivers are shared across the whole industry, which is why it is defensive:

• Aging and chronic disease. Older, sicker populations consume more medicine, run more diagnostic tests, and receive more biologics — the structural, non-cyclical base under all four children. Census projects the share of Americans aged 65 and older will surpass the share under 18 in 2029 [23].
• The obesity/GLP-1 wave. GLP-1 drugs (glucagon-like peptide-1 receptor agonists — the diabetes/weight-loss class including semaglutide and tirzepatide) are the single biggest growth engine, roughly 29% of all 2024 U.S. drug-spending growth [5]. They pull demand through three children at once: finished-drug capacity (325412), peptide-substance and API work (325411), and fill-finish.
• The shift toward biologics. Large-molecule medicines are now roughly 37–38% of U.S. prescription-drug spending and the fastest-growing slice [9] — a tailwind for 325414 and a mild headwind for the small-molecule chemistry of 325411.
• Molecular and point-of-care testing. The fastest-growing diagnostics categories broaden the reagent base in 325413, and companion diagnostics tie test demand to the drug pipeline.
• Supply-security and reshoring policy. Tariffs, supply-chain-security programs, and reshoring incentives are now a demand driver in their own right for domestic capacity across every child (Sections 7–8).

---

7. Regulation

Medicine manufacturing is among the most heavily regulated activity in the economy, and the FDA is the common overlord — current Good Manufacturing Practice (cGMP), routine plant inspections, and the power to issue warning letters, import alerts, and recalls apply across all four children. Above that shared floor, each child has its own approval regime and its own policy pressures.

• Approval pathways differ by child. Finished small-molecule drugs (325412) clear a New Drug Application (NDA) or, for generics, an Abbreviated New Drug Application (ANDA) under the Hatch-Waxman framework. Biologics (325414) clear a Biologics License Application (BLA) under the Public Health Service Act, with biosimilars using the abbreviated 351(k) route created by the Biologics Price Competition and Innovation Act (BPCIA) — FDA had approved 82 biosimilars as of March 2026 [2]. Diagnostic reagents (325413) are cleared as medical devices via 510(k), De Novo, or Premarket Approval (PMA), and their lab customers are governed by the Clinical Laboratory Improvement Amendments (CLIA). Bulk APIs (325411) file confidential Drug Master Files and, for scheduled substances, operate only under Drug Enforcement Administration (DEA) production quotas.
• Drug-pricing policy hits the two drug children hardest. The Inflation Reduction Act (IRA) lets Medicare (through CMS, the Centers for Medicare & Medicaid Services) negotiate prices on its most expensive drugs; the first 10 negotiated prices take effect January 2026, at least 38% below 2023 list prices [24], and the program widens each year — a structural headwind to branded pricing in 325412 and, on a longer clock, 325414. Notably, biologics get about 13 years of market pricing before negotiation bites versus 9 years for small-molecule pills, a gap that steers investment toward large molecules [25].
• Trade policy now cuts across everything. Under a Section 232 (national-security) action, an April 2026 proclamation imposed tariffs on certain patented pharmaceutical products and ingredients with a tiered structure: a 100% default rate, cut to 20% for companies with approved onshoring plans, 15% for products from the EU, Japan, South Korea, and Switzerland, and 0% for firms that sign pricing-and-onshoring agreements. Duties phase in from July 31, 2026 (named companies) and September 29, 2026 (all others) [26]. The underlying Commerce investigation found only about 15% of patented APIs by volume are produced domestically [26]. Reagent and biologics imports face their own tariff exposure. The stated aim is to pull manufacturing — especially the imported API base — back onshore.
• Diagnostics has its own live swing. The FDA's May 2024 rule to regulate laboratory-developed tests (LDTs) as devices was vacated by a federal court in March 2025 and then formally rescinded in September 2025 [27], leaving kit makers (325413) fully FDA-regulated while their lab-based competitors running LDTs are not — a competitive asymmetry unique to that child. Separately, CMS indicates that Clinical Laboratory Fee Schedule (CLFS) payment reductions may be as much as 15% per year through 2029, squeezing the lab customers who buy reagents [28].

---

8. Consolidation

Start with a warning about the headline numbers. By the federal concentration data, the industry as a whole looks strikingly unconcentrated: the top four firms hold only 28.4% of revenue and the HHI is 313.7 [3], far below the 1,500 threshold antitrust regulators treat as concentrated. But that is partly a statistical illusion of aggregation — notice that the group's HHI (314) is lower than that of its dominant child, finished drugs (557), and of diagnostics (752). Pooling four industries whose leaders are largely different companies competing in different markets mechanically dilutes measured concentration. The real competitive picture is the opposite: within any single disease, drug, testing category, or plasma market, a patented product or platform can be a near-monopoly, and the plasma business is a tight oligopoly (CSL, Grifols, Takeda, and Octapharma control an estimated 70–80% of U.S. collection and fractionation [29]).

The actual consolidation is intense and runs on several tracks:

• M&A as pipeline insurance. Facing an unusually large 2026–2030 patent cliff — the U.S. market is projected to lose over $230 billion in revenue across roughly 190 drugs, about 69 of them blockbusters [30] — large drugmakers buy smaller ones to refill pipelines. 2025 pharma M&A reached about $240 billion, up 81% year over year [31].
• Contract-manufacturing roll-up. The independent CDMO tier is consolidating as customers seek one partner from development through commercial supply — Novo Holdings' $16.5 billion Catalent take-private is the emblem [16], and roughly $24.9 billion in new CDMO capacity was announced in 2025, ~74% of it flowing to the United States [32].
• Diagnostics portfolio reshuffling. QuidelOrtho's 2022 merger (~$6 billion) and Becton Dickinson's ~$17.5 billion combination of its diagnostics business into Waters (closed February 2026) show the same scale logic in reagents [33].
• The reshoring capex cycle. Under tariff and supply-security pressure, drugmakers have pledged on the order of $500 billion in new U.S. manufacturing, with nearly $283 billion pledged since the 2025 trade action opened — a slice explicitly aimed at the API and biologics capacity the country most lacks [34]. Whether that durably rebuilds the low-margin, cost-disadvantaged domestic API base is the open question.

---

9. Risks

Because the four children share a regulator and a customer base, several risks apply industry-wide; others are child-specific.

• Patent and exclusivity cliffs (325412, 325414). The defining risk of the drug children: a top product's revenue can fall 80–90% within a year of generic or biosimilar entry, and 2026–2030 is an exceptionally heavy expiry wave [30].
• Pricing and policy pressure (industry-wide, worst for drugs). IRA Medicare negotiation, expanding each year, plus middleman (pharmacy benefit manager) reform and general political hostility to drug prices, structurally compress branded pricing power [24].
• Import dependence, supply shocks, and tariff whiplash. Most bulk APIs and much finished/biologic/reagent product is imported; U.S. pharmaceutical imports jumped from $73 billion (2014) to $215 billion (2024) [34], and FDA reports only 11% of API manufacturers are U.S.-based [6]. New tariffs raise costs — and can raise the cost of the very imported inputs that domestic producers still depend on — a two-edged sword until upstream chemistry is also reshored [26].
• Manufacturing and quality failure (industry-wide). A failed FDA inspection, contamination, batch loss, or impurity finding can halt a product line overnight. FDA states that manufacturing-quality problems are the most common cause of drug shortages, and that long lead times and limited alternative capacity make rapid recovery difficult [35].
• Pipeline and single-product binary risk (325412, 325414). Most drug candidates fail; because value is so concentrated in individual products, single-stock outcomes can be unusually all-or-nothing.
• Child-specific tails. Controlled-substance and opioid litigation (325411); plasma-supply and paid-donor dependence, plus lumpy government demand (325414); post-COVID revenue normalization (Abbott's COVID rapid-test sales fell from $725 million in 2024 to $285 million in 2025 [36]) and reimbursement (CLFS/PAMA) pressure on lab customers (325413); commodity-generic deflation and a structural cost disadvantage versus India and China (325411).

---

10. How to invest, and the outlook

Map the route to the child you want.

• Broad, liquid, defensive exposure → 325412. Mature branded drugmakers (JNJ, MRK, ABBV, AZN, NVS) are profitable, dividend-paying, and driven by drug-specific rather than economic-cycle risk; growth leaders (LLY, NVO) ride the obesity/GLP-1 boom at higher valuations. Generics/CDMOs (TEVA, VTRS, TMO) are volume-and-consolidation plays. Sector and biotech exchange-traded funds (ETFs) spread single-drug risk.
• The fastest-growing slice → 325414. Near pure-plays (ADMA, MRNA, NVAX, EBS), plasma majors (CSL, GRFS, TAK), diversified pharma with big biologic franchises, and picks-and-shovels contract makers and bioprocessing-tools suppliers (Lonza, Thermo Fisher, Danaher, Sartorius, Repligen).
• A sticky, high-quality annuity → 325413. The diversified leaders (ABT, DHR, TMO, RHHBY, SHL) where diagnostics is a large, high-margin segment, or harder-tilted mid-caps (QDEL, HOLX, BIO, QGEN) for more concentrated — and more volatile — exposure.
• The strategic, contested upstream → 325411. No U.S. pure-play; assemble it from foreign-listed API/CDMO specialists (Lonza, Divi's, Dr. Reddy's, Siegfried), U.S. diversified names (TMO, MNK, AMPH), and ingredient/nutrition firms (DSM-Firmenich, Balchem, IFF).
• The purest assets are private, in every child. Private-equity healthcare and specialty-chemicals funds, venture capital in clinical-stage biotech and early diagnostics developers, drug-royalty deals, direct/co-investment in private CDMOs and plasma fractionators, and — for biodefense/vaccines — government-contractor plays.

Near-term drivers to watch (forward-looking). The 2026–2030 patent cliff [30] will separate companies that refilled their pipelines from those that didn't, and should keep M&A elevated [31]. IRA price negotiation takes real effect in 2026 and widens annually — a persistent branded-pricing headwind [24]. Tariffs and the ~$500 billion reshoring wave [26][32] will reshape where medicine is made, with the biggest question being whether the low-margin API base actually comes home. The obesity/GLP-1 franchise remains the dominant growth story, pulling capacity through multiple children at once.

The reasonable read. Expect durable, largely recession-proof volume growth in medicine overall; branded pricing power narrowing under policy pressure; biologics (325414) taking a rising share of both spending and new capacity; diagnostics (325413) compounding steadily as an annuity; and a gradual, capital-intensive, and incomplete reshoring of the API base (325411) that is real but constrained by a persistent cost gap. The industry stays large, defensive, and profitable — but the growth, the risk, and the way to own it differ sharply depending on which of the four children you are actually buying.

---

Sources

1. Centers for Disease Control and Prevention. "Prevalence of Chronic Conditions Among US Adults, 2023." Preventing Chronic Disease. 2025. https://www.cdc.gov/pcd/issues/2025/24_0539.htm
2. U.S. Food and Drug Administration. "FDA Takes Further Steps to Streamline Biosimilar Development" (82 biosimilars approved; biologics 5% of prescriptions, 51% of spending). March 2026. https://www.fda.gov/news-events/press-announcements/fda-takes-further-steps-streamline-biosimilar-development-and-make-medicines-more-affordable
3. U.S. Census Bureau. "2022 Economic Census — Concentration Ratios and Receipts, NAICS 32541" (receipts, firms, CR4 28.4% / CR8 40.8% / CR20 57.4% / CR50 71.6%, HHI 313.7). Ground-truth federal data. https://www.census.gov/programs-surveys/economic-census.html
4. U.S. Census Bureau. "County Business Patterns 2023 — NAICS 32541" (establishments 2,905; employment 321,068; annual payroll ~$36.5B). Ground-truth federal data. https://www.census.gov/programs-surveys/cbp.html
5. PharmExec (MJH Life Sciences) / ASHP. "GLP-1 Surge Fuels 10.2% Rise in US Prescription Drug Spending in 2024" ($805.9B; GLP-1 ~29% of growth). 2025. https://www.pharmexec.com/view/glp-1-surge-fuels-10-2-rise-us-prescription-drug-spending-2024
6. U.S. Food and Drug Administration. "FDA Manufacturing PreCheck Pilot Program" (53% branded / 69% generic finished drugs manufactured abroad; 11% API manufacturers US-based). 2025. https://www.fda.gov/industry/fda-manufacturing-precheck-pilot-program
7. Grand View Research. "U.S. Active Pharmaceutical Ingredients Market Report" (~$87B, 2024). 2024. https://www.grandviewresearch.com/industry-analysis/us-active-pharmaceutical-ingredients-market-report
8. Nova One Advisor / Precedence Research. "U.S. In Vitro Diagnostics Market Size" (~$35B, 2024; reagents ~two-thirds). 2025. https://www.novaoneadvisor.com/report/in-vitro-diagnostics-ivd-market
9. Grand View Research / JAMA. "Biologics Market; biologics ~37–38% of U.S. drug spending; U.S. market >$200B." 2025. https://www.grandviewresearch.com/industry-analysis/biologics-market
10. PhRMA / TEConomy Partners. "The Economic Impact of the U.S. Biopharmaceutical Industry" (~$96B R&D in 2023; >1M direct jobs). 2024. https://phrma.org/resources/industry-economic-impact
11. Fierce Pharma. "The top 20 pharma companies by 2025 revenue." 2026. https://www.fiercepharma.com/special-reports/top-20-pharma-companies-2025-revenue
12. Statista / BioSpace / DrugPatentWatch. "Keytruda ~$32B (2025)." 2025. https://www.statista.com/statistics/258022/top-10-pharmaceutical-products-by-global-sales-2011/
13. The Dark Report (Dark Intelligence Group). "2025 Ranking of the World's Top 13 IVD Corporations" (top-13 diagnostic revenue ~$91.9B in 2024). 2025. https://www.darkintelligencegroup.com/the-dark-report/in-vitro-diagnostics/2025-ranking-of-the-worlds-top-13-ivd-corporations/
14. Lonza Group AG. "2025 Financial Report" (CHF 6.5B sales, 31.6% CORE EBITDA margin). 2026. https://www.lonza.com/annualreport/2025/pages/financials
15. Siegfried Holding. "Full-Year Results 2025 Media Release" (23.5% core EBITDA margin). 2026. https://www.siegfried.ch/app/uploads/2026/02/20260220_Siegfried_Media-Release_FYR-2025_EN.pdf
16. BioProcess International. "Novo Holdings to buy CDMO Catalent for $16.5bn." 2024. https://www.bioprocessintl.com/facilities-capacity/novo-holdings-16-5bn-catalent-buy-to-boost-fill-finish-for-novo-nordisk-
17. Eli Lilly and Company. Form 10-K (FY2025) (consolidated gross margin ~83%). U.S. SEC. 2026. https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/lly-20251231.htm
18. Teva Pharmaceutical Industries. Form 8-K (Q1 2026 results; 49.5% gross margin). U.S. SEC. 2026. https://www.sec.gov/Archives/edgar/data/0000818686/000117184326002796/exh_991.htm
19. Viatris Inc. Form 10-K (FY2025; 35% gross margin). U.S. SEC. 2026. https://www.sec.gov/Archives/edgar/data/1792044/000179204426000013/vtrs-20251231.htm
20. Bloomberg Law / GaBI Online. "The Biologics Price Competition and Innovation Act — 12-year exclusivity." 2024. https://gabionline.net/biosimilars/general/Biosimilars-and-US-exclusivity
21. CNBC / Econlib / Newsweek. "Why blood makes up over 2.5% of U.S. exports; U.S. ~70% of world source plasma." 2022–2025. https://www.cnbc.com/2022/06/30/why-blood-makes-up-over-2point5percent-of-all-us-exports.html
22. Danaher Corporation. 2025 Annual Report (Diagnostics segment $9.94B; 89% recurring products). U.S. SEC. https://www.sec.gov/Archives/edgar/data/313616/000031361626000105/danaher2025annualreport.htm
23. U.S. Census Bureau. "2023 Population Projections" (65+ to surpass under-18 in 2029). 2023. https://www.census.gov/newsroom/press-releases/2023/population-projections.html
24. Centers for Medicare & Medicaid Services. "Medicare Drug Price Negotiation Program: Negotiated Prices for 2026" (first 10 prices, ≥38% below 2023 list). 2025. https://www.cms.gov/newsroom/fact-sheets/medicare-drug-price-negotiation-program-negotiated-prices-initial-price-applicability-year-2026
25. Congressional Research Service / KFF. "Medicare Drug Price Negotiation under the IRA" (biologics eligible after 11 years; 13 vs 9 years market pricing). 2025. https://www.congress.gov/crs-product/R47872
26. The White House / Crowell & Moring / BioPharma Dive. "Section 232 tariffs on patented pharmaceutical products and ingredients" (100% default, tiered carve-outs; ~15% of patented APIs by volume domestic; phasing in from July 31, 2026). 2026. https://www.whitehouse.gov/fact-sheets/2026/04/fact-sheet-president-donald-j-trump-bolsters-national-security-and-strengthens-u-s-supply-chains-by-imposing-tariffs-on-patented-pharmaceutical-products/
27. Covington & Burling / Arnold & Porter. "FDA's LDT Rule Struck Down" (May 2024 rule; vacated March 2025; rescinded September 2025). 2025. https://www.cov.com/en/news-and-insights/insights/2025/04/fdas-ldt-rule-struck-down-by-federal-district-court
28. Centers for Medicare & Medicaid Services. "Clinical Laboratory Fee Schedule (CLFS) and PAMA reporting resources" (2027 reset; up to 15% annual cuts through 2029). https://www.cms.gov/medicare/payment/fee-schedules/clinical-laboratory-fee-schedule/clfs-pama-reporting-resources
29. PR Newswire / MarketsandMarkets. "Plasma Fractionation Market — CSL, Grifols, Takeda, Octapharma (~70–80% U.S.)." 2024–2025. https://www.marketsandmarkets.com/ResearchInsight/plasma-fractionation-market.asp
30. Drug Discovery News. "Blockbuster drugs face a massive patent cliff in 2026" (>$230B, ~190 drugs, ~69 blockbusters, 2025–2030). 2025. https://www.drugdiscoverynews.com/blockbuster-drugs-face-a-massive-patent-cliff-in-2026-17019
31. BS Capital Markets. "Patent Cliffs and the New Pharma M&A Cycle" (2025 M&A ~$240B, +81% YoY). 2026. https://www.bscapitalmarkets.com/patent-cliffs-and-the-new-pharma-ma-cycle.html
32. PharmaSource. "The Great Reshoring: How $24.86 Billion Reshaped CDMO Manufacturing in 2025" (~74% to U.S.). 2025. https://pharmasource.global/content/news/cdmo-news/the-great-reshoring-how-24-86-billion-reshaped-cdmo-manufacturing-in-2025/
33. Becton Dickinson / Waters Corporation. "BD to combine Biosciences and Diagnostic Solutions with Waters" (Reverse Morris Trust, ~$17.5B; closed Feb 2026). U.S. SEC Form 8-K/425. 2025. https://www.sec.gov/Archives/edgar/data/10795/000119312525158404/d41030dex991.htm
34. Coalition for a Prosperous America. "Skyrocketing Pharmaceutical Imports to the U.S." (imports $73B→$215B; ~$283B reshoring pledges post trade action). 2025. https://prosperousamerica.org/skyrocketing-pharmaceutical-imports-to-the-u-s-endanger-national-security/
35. U.S. Food and Drug Administration. "Frequently Asked Questions About Drug Shortages" (manufacturing quality as most common cause). 2025. https://www.fda.gov/drugs/drug-shortages/frequently-asked-questions-about-drug-shortages
36. Abbott Laboratories. Form 10-K FY2025 (COVID rapid-test decline $725M→$285M). U.S. SEC. https://www.sec.gov/Archives/edgar/data/1800/000162828026010185/abt-20251231.htm